ARRY-502: Additional Phase II data

Additional data from a pre-defined subset of patients with an elevated median baseline value of fractional exhaled nitric oxide (FeNO) in a double-blind, U.S. Phase II trial showed that twice-daily 200 mg oral ARRY-502 significantly improved median pre-bronchodilator FEV1 from baseline to day 29 by 6.8% adjusted to placebo (p=0.008). In July, Array said ARRY-502 improved FEV1 by 6.8% in a pre-defined subset of patients based on the median baseline value of a T helper type 2 (Th2)-associated biomarker, but did not disclose FeNO as the biomarker (see BioCentury, July 29, 2013). ...